Tamsulosin versus transurethral resection of the prostate: Effect on nocturia as a result of benign prostatic hyperplasia
Tamsulosin versus transurethral resection of the prostate: Effect on nocturia as a result of benign prostatic hyperplasia
复制标题
坦索罗辛与经尿道前列腺电切术：对良性前列腺增生所致夜尿症的影响
DOI：
--
复制
发表时间：
2011
影响因子：
2.6
通讯作者：
C. Deliveliotis
中科院分区：
文献类型：
--
作者：
V. Simaioforidis;A. Papatsoris;M. Chrisofos;Manolis Chrisafis;S. Koritsiadis;C. Deliveliotis
我们的目的是比较坦索罗辛与经尿道前列腺电切术 (TURP) 对先前未经治疗的男性夜尿症的治疗效果，这些男性的下尿路症状 (LUTS) 提示良性前列腺增生 (BPH)，且无其他夜尿症诱发因素。研究组包括 66 名患者（平均年龄 68.9 岁，范围 52-81），随机接受每日口服坦索罗辛 0.4 毫克 (n=33) 或 TURP (n=33)。通过从 72 小时频率容量图 (FVC) 获得的夜间觉醒次数和不受干扰睡眠时间 (HUS) 在基线、3 个月后和 1 年后评估夜尿症。此外，还记录了国际前列腺症状评分（IPSS）、夜尿失禁问卷国际咨询（ICIQ-N）和夜尿失禁问卷国际生活质量咨询（ICIQ-NQoL）。在基线时，两组之间没有统计学上的显着差异。 ICIQNQoL 和 ICIQ-N 评分分别与觉醒次数和 HUS 相关。坦索罗辛和 TURP 在随访期间均改善了所有检查参数。与坦索罗辛相比，TURP 与夜间觉醒次数以及 IPSS、ICIQ-N 和 ICIQ-NQol 评分的统计显着改善相关。两组的 HUS 均有所增加，但没有任何统计学上的显着差异。总之，TURP 在治疗 BPH 相关夜尿方面优于坦索罗辛。
Our objective was to compare the effect of tamsulosin versus transurethral resection of the prostate (TURP) for the management of nocturia in previously untreated men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and no other predisposing factors for nocturia. The study group included 66 patients (mean age 68.9 years, range 52–81) randomized to receive either tamsulosin 0.4 mg per os daily (n = 33) or TURP (n = 33). Nocturia was assessed at baseline, after 3 months and after 1 year, by the number of nocturnal awakenings and hours of undisturbed sleep (HUS) obtained from a 72‐h Frequency Volume Chart (FVC). Furthermore, the International Prostate Symptom Score (IPSS), the International Consultation on Incontinence Questionnaire Nocturia (ICIQ‐N) and the International Consultation on Incontinence Questionnaire Nocturia Quality of Life (ICIQ‐NQoL) were recorded. At baseline, there were no statistically significant differences between the two groups. ICIQNQoL and ICIQ‐N scores correlated with the number of awakenings and HUS, respectively. Both tamsulosin and TURP improved all examined parameters during the follow up. TURP was associated with a statistically significant improvement in the number of nocturnal awakenings and in the IPSS, ICIQ‐N and ICIQ‐NQol scores in comparison with tamsulosin. HUS increased in both groups, but without any statistically significant difference. In conclusion, TURP is superior in comparison with tamsulosin for the management of BPH‐related nocturia.